- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00540657
A Phase II Study of CCX282-B in Patients With Celiac Disease
August 24, 2023 updated by: ChemoCentryx
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease
The purpose of this study is to determine whether CCX282-B is effective in mitigating the effects of gluten ingestion in patients with celiac disease
Study Overview
Study Type
Interventional
Enrollment (Estimated)
90
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tampere, Finland, FIN-33520
- Finn-Medi Research Ltd, Outpatient Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Male or female, between 18 and 75 years of age
- Established diagnosis of celiac disease
- Subject has been following a strict gluten-free diet for at least 24 months
Key Exclusion Criteria:
- History of any infection requiring intravenous antibiotics, a serious local infection, systemic infection, or gastrointestinal infection within 12 weeks of randomization
- Use of any immunosuppressants, TNF inhibitors, or natalizumab during the 12 weeks prior to study randomization
- Use of steroids during the 4 weeks prior to study randomization
- Receipt of an experimental treatment for any disease within 4 weeks prior to randomization
- Known IgE-mediated atopy or allergy or anaphylactic reactions to gluten
- The subject suffers from a condition that carries a risk at endoscopy or is on anticoagulant treatment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
250mg capsule, twice daily, 13 weeks
|
Placebo Comparator: 2
|
Placebo capsule, twice daily, 13 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Evaluation of the effect of CCX282-B compared to placebo on the villous height/crypt depth ratio of small intestinal biopsy specimens taken from subjects with celiac disease, before and after gluten exposure.
|
Secondary Outcome Measures
Outcome Measure |
---|
Evaluation of CCX282-B compared to placebo on small intestinal mucosal inflammation before and after gluten exposure
|
Evaluation of CCX282-B compared to placebo on gluten-induced celiac-type serology before and after gluten exposure
|
Evaluation of CCX282-B compared to placebo on symptom scores before and after gluten exposure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: MD, Amgen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
June 1, 2008
Study Completion (Actual)
July 1, 2008
Study Registration Dates
First Submitted
October 5, 2007
First Submitted That Met QC Criteria
October 5, 2007
First Posted (Estimated)
October 8, 2007
Study Record Updates
Last Update Posted (Actual)
August 25, 2023
Last Update Submitted That Met QC Criteria
August 24, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL009_282
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Celiac Disease
-
University of OxfordCompletedCeliac Disease | Mental Health Wellness 1 | Emotional Problem | Stigma, Social | Celiac Disease in Children | Celiac | DisclosureUnited Kingdom
-
IRCCS Burlo GarofoloRecruitingCeliac Disease in ChildrenItaly
-
Cairo UniversityNot yet recruitingCeliac Disease in Children
-
Meir Medical CenterTerminatedCeliac Disease in ChildrenIsrael
-
Schneider Children's Medical Center, IsraelUnknownCeliac Disease in ChildrenIsrael
-
University of PalermoCompletedNot-celiac Gluten (Wheat) SensitivityItaly
-
University of PalermoRecruiting
-
University of PalermoCompletedNot-celiac Gluten SensitivityItaly
-
ASST Fatebenefratelli SaccoNot yet recruiting
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentEnrolling by invitationCeliac Disease in ChildrenNetherlands
Clinical Trials on CCX282-B
-
ChemoCentryxCompletedCrohn's DiseaseBrazil, Australia, Israel, Belgium, France, Canada, Germany, Denmark, Hungary, Bulgaria, Sweden, Netherlands, Austria, Poland, South Africa, United Kingdom, Czechia
-
ChemoCentryxCompletedCrohn DiseaseUnited States
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
National Institute of Allergy and Infectious Diseases...Dynavax Technologies CorporationActive, not recruitingHIV Infection | Hepatitis BUnited States, Haiti, Botswana, Philippines, Thailand, Brazil, Kenya, Malawi, India, South Africa, Uganda, Vietnam
-
Indiana UniversityAlcon ResearchCompleted
-
PfizerCompletedA Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804Healthy VolunteersBelgium
-
Marya Strand, MDCompletedRespiratory Distress SyndromeUnited States
-
ChemoCentryxMedpace, Inc.CompletedFocal Segmental Glomerulosclerosis | FSGS | GlomerulosclerosisUnited States, France, Italy, Australia, United Kingdom, Canada, New Zealand, Poland
-
Soroka University Medical CenterCompletedInflammatory Bowel DiseaseIsrael
-
Epstein, Arthur B., OD, FAAOAlcon ResearchCompleted